229484-80-4

Basic information

• Product Name: Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 8-[(2,6-difluorophenyl)methyl]-2-[4-[[(ethylamino)carbonyl]amino]phenyl]- 5,8-dihydro-3-[[methyl(phenylmethyl)amino]methyl]-5-oxo-, ethyl ester
• CAS NO: 229484-80-4
• Molecular Formula: C34H34F2N6O4
• Molecular Weight: 628.679
• Mol File: 229484-80-4.mol

Chemical Properties

• CAS DataBase Reference: Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 8-[(2,6-difluorophenyl)methyl]-2-[4-[[(ethylamino)carbonyl]amino]phenyl]- 5,8-dihydro-3-[[methyl(phenylmethyl)amino]methyl]-5-oxo-, ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 8-[(2,6-difluorophenyl)methyl]-2-[4-[[(ethylamino)carbonyl]amino]phenyl]- 5,8-dihydro-3-[[methyl(phenylmethyl)amino]methyl]-5-oxo-, ethyl ester(229484-80-4)
• EPA Substance Registry System: Imidazo[1,2-a]pyrimidine-6-carboxylic acid, 8-[(2,6-difluorophenyl)methyl]-2-[4-[[(ethylamino)carbonyl]amino]phenyl]- 5,8-dihydro-3-[[methyl(phenylmethyl)amino]methyl]-5-oxo-, ethyl ester(229484-80-4)

Safety Data

• Hazardous Substances Data: 229484-80-4(Hazardous Substances Data)

Upstream product

• 229484-63-3 8-(2,6-difluorobenzyl)-5,8-dihydro-3-(N-methyl-N-benzylaminomethyl)-2-(4-nitrophenyl)-5-oxoimidazo[1,2-a]pyrimidine-6-carboxylic acid ethyl ester 
• 229484-53-1 3-bromomethyl-8-(2,6-difluorobenzyl)-5,8-dihydro-2-(4-nitrophenyl)-5-oxoimidazo[1,2-a]pyrimidine-6-carboxylic acid ethyl ester 
• 229484-52-0 8-(2,6-difluorobenzyl)-5,8-dihydro-3-methyl-2-(4-nitrophenyl)-5-oxoimidazo[1,2-a]pyrimidine-6-carboxylic acid ethyl ester 
• 229484-43-9 8-(2,6-difluorobenzyl)-5,8-dihydro-3-methyl-5-oxo-2-phenylimidazo[1,2-a]pyrimidine-6-carboxylic acid ethyl ester 
• 229484-39-3 ethyl 5,8-dihydro-3-methyl-5-oxo-8-(1-oxo-1-phenylpropan-2-yl)-2-phenylimidazo[1,2-a]pyrimidine-6-carboxylate 
• 229485-47-6 5-hydroxy-3-methyl-2-phenylimidazo[1,2-a]pyrimidine-6-carboxylic acid ethyl ester 
• 697-73-4 2,6-difluorobenzyl chloride 
• 15400-53-0 ethyl 2-amino-4-hydroxypyrimidine-5-carboxylate 
• 109-90-0 ethyl isocyanate 
• 229484-76-8 2-(4-aminophenyl)-8-(2,6-difluorobenzyl)-5,8-dihydro-3-(N-methyl-N-benzylaminomethyl)-5-oxoimidazo[1,2-a]pyrimidine-6-carboxylic acid ethyl ester 

Relevant articles and documents

Synthesis and evaluation of homo-bivalent GnRHR ligands

G protein coupled receptors (GPCRs) are important drug targets in pharmaceutical research. Traditionally, most research efforts have been devoted towards the design of small molecule agonists and antagonists. An interesting, yet poorly investigated class of GPCR modulators comprise the bivalent ligands, in which two receptor pharmacophores are incorporated. Here, we set out to develop a general strategy for the synthesis of bivalent compounds that are projected to bind to the human gonadotropin-releasing hormone receptor (GnRHR). Our results on the dimerisation of a known GnRHR antagonist, with as key step the Huisgen 1,3-cycloaddition, and their ability to bind to and antagonize GnRH-induced GnRHR stimulation, are presented here.

A new class of potent nonpeptide luteinizing hormone-releasing hormone (LHRH) antagonists: design and synthesis of 2-phenylimidazo[1,2-a]pyrimidin-5-ones.

The design and synthesis of a new class of nonpeptide luteinizing hormone-releasing hormone (LHRH) receptor antagonists, the 2-phenylimidazo[1,2-a]pyrimidin-5-ones, is reported. Among compounds described in this study, we identified the potent antagonist 15b with nanomolar in vitro functional antagonism. The result might suggest that the heterocyclic 5-6-ring system possessing a pendant phenyl group attached to the five-membered ring is the important structural feature for a scaffold of small molecule LHRH antagonists.

Nitrogen-containing heterocyclic compounds, their production and use

A compound of the formula: wherein one of A and D is N and the other is C, or both are N; B is N or C; m is 0-3; R1, R2 and R3 each is (i) H or (ii) a group bound via C, N, O or S; R4 is a group bound via C; R5 is H or a group bound via C or O; R6 is H or a group bound via C; R7 is a homo- or hetero-cyclic group which may be substituted; or a salt thereof possesses excellent gonadotropin-releasing hormone antagonizing activity, and is useful as a prophylactic or therapeutic agent for sex hormone-dependent diseases, and so forth.